Search research articles
Contact Us
Filters
Showing results (861-870 of 993) with videos related to
Page
of 100
Sort By:
Urologic Oncology
|
November 13, 2024
Primary tumor ablation in metastatic renal cell carcinoma
Lukas Scheipner, Reha-Baris Incesu, Simone Morra, et al.
Cancer Medicine
|
November 11, 2024
Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis
Motohide Uemura, Hiroaki Kikukawa, Yasuhiro Hashimoto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2024
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
The New England Journal of Medicine
|
August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapy
Howard I Scher, Karim Fizazi, Fred Saad, et al.
Journal of Surgical Oncology
|
March 28, 2025
Robot-Assisted Versus Open Radical Cystectomy: Comparison of Adverse In-Hospital Outcomes
Francesco Di Bello, Natali Rodriguez Peñaranda, Andrea Marmiroli, et al.
Urologic Oncology
|
March 9, 2025
Cirrhosis and liver disease vs. adverse in-hospital outcomes after radical prostatectomy
Fabian Falkenbach, Natali Rodriguez Peñaranda, Mattia Longoni, et al.
Clinical Genitourinary Cancer
|
December 11, 2024
Trends and Disparities in Inpatient Palliative Care Use in Metastatic Renal Cell Carcinoma Patients Receiving Critical Care Therapy
Carolin Siech, Simone Morra, Lukas Scheipner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 26, 2024
Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study
Frédéric Pouliot, Fred Saad, Etienne Rousseau, et al.
International Urology and Nephrology
|
August 11, 2024
Differences in life expectancy of adrenocortical carcinoma patients vs. age‑ and sex-matched population controls
Letizia Maria Ippolita Jannello, Andrea Baudo, Lukas Scheipner, et al.
British Journal of Cancer
|
November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN
John Shen, Simon Chowdhury, Neeraj Agarwal, et al.
Page
of 100
Search research articles
Search
Showing results (861-870 of 993) with videos related to
Sort By:
Page
of 100
Urologic Oncology
|
November 13, 2024
Primary tumor ablation in metastatic renal cell carcinoma
Lukas Scheipner, Reha-Baris Incesu, Simone Morra, et al.
Cancer Medicine
|
November 11, 2024
Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis
Motohide Uemura, Hiroaki Kikukawa, Yasuhiro Hashimoto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2024
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
The New England Journal of Medicine
|
August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapy
Howard I Scher, Karim Fizazi, Fred Saad, et al.
Journal of Surgical Oncology
|
March 28, 2025
Robot-Assisted Versus Open Radical Cystectomy: Comparison of Adverse In-Hospital Outcomes
Francesco Di Bello, Natali Rodriguez Peñaranda, Andrea Marmiroli, et al.
Urologic Oncology
|
March 9, 2025
Cirrhosis and liver disease vs. adverse in-hospital outcomes after radical prostatectomy
Fabian Falkenbach, Natali Rodriguez Peñaranda, Mattia Longoni, et al.
Clinical Genitourinary Cancer
|
December 11, 2024
Trends and Disparities in Inpatient Palliative Care Use in Metastatic Renal Cell Carcinoma Patients Receiving Critical Care Therapy
Carolin Siech, Simone Morra, Lukas Scheipner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 26, 2024
Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study
Frédéric Pouliot, Fred Saad, Etienne Rousseau, et al.
International Urology and Nephrology
|
August 11, 2024
Differences in life expectancy of adrenocortical carcinoma patients vs. age‑ and sex-matched population controls
Letizia Maria Ippolita Jannello, Andrea Baudo, Lukas Scheipner, et al.
British Journal of Cancer
|
November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN
John Shen, Simon Chowdhury, Neeraj Agarwal, et al.
Page
of 100